-
FDA Issues Complete Response Letter for Deramiocel
Today, the FDA announced that it has issued a Complete Response Letter (CRL) for Capricor Therapeutics’ Biologics License Application (BLA) for Deramiocel (CAP-1002), the company’s cell therapy for Duchenne cardiomyopathy. This decision is devastating and means that the current application will not be approved. This is heartbreaking news for the Duchenne community, particularly for individuals…
-
FDA declines to approve Capricor’s deramiocel for the treatment of Duchenne
Despite recognition of the tremendous unmet medical need in Duchenne muscular dystrophy, the FDA has decided that the evidence is not sufficient to approve Capricor’s deramiocel for the treatment of Duchenne and issued a Complete Response Letter to the company this afternoon. This decision has come after a review of the original application, a public…








